Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Myeloid 1Head & Neck 1Gastrointestinal 1CNS 1

Conditions

Colorectal Neoplasms 21Colonic Neoplasms 3Carcinoma, Renal Cell 3Carcinoma, Non-Small-Cell Lung 3Uterine Cervical Neoplasms 2Stomach Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Ovarian Neoplasms 2Neoplasm Metastasis 2Melanoma 2Lung Neoplasms 2Carcinoma, Neuroendocrine 2Brain Neoplasms 2Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Solid Tumors 1Small Cell Lung Carcinoma 1Rectal Neoplasms 1Ras-mutated Metastatic Colorectal Cancer 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Pancreatic Adenocarcinoma Metastatic 1Neoplasms 1Kidney Neoplasms 1Histiocytosis 1Head and Neck Neoplasms 1Glioblastoma 1Gastrointestinal Neoplasms 1Gastroesophageal Adenocarcinoma 1

Interventions

Panitumumab 1IFL protocol 1Gemcitabine 1Cetuximab 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Histiocytosis × IFL protocol × 1 year × Clear all
NCT05786924 2026-04-21

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

Servier

Phase 1/2 Recruiting
554 enrolled
CNSGastrointestinalHead & NeckMyeloidThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Thyroid Neoplasms, Colorectal Neoplasms, Histiocytosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡